

## **AUTHOR GUIDELINES**

### **Journal scope and general principles**

European Annals of Allergy and Clinical Immunology is a bimonthly peer-reviewed publication. As official Journal of the "Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri" (Association of Italian Hospital Allergists and Immunologists - AAIIITO) and the "Sociedade Portuguesa de Alergologia e Immunologia Clinica" (Portuguese Society of Allergology and Clinical Immunology - SPAIC), it collects reviews, original works and case reports, although to a lesser extent, concerning etiology, diagnosis and treatment of allergic and immunological disorders. It includes a section of information coming from the main international health associations and authorities.

European Annals of Allergy and Clinical Immunology represents to the specialist a means for updating and widening in research and clinical practice field.

European Annals of Allergy and Clinical Immunology will accept for publication suitable manuscripts dealing with the aetiology, diagnosis and treatment of allergic and immunologic diseases. These might include the study of methods of controlling immunologic and allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense. Paper reporting the results of drug trials will be considered.

European Annals of Allergy and Clinical Immunology also publishes solicited and unsolicited review articles on subjects of topical interest to clinical and experimental allergy.

Manuscripts are considered for publication with the understanding that they do not contain previously published material, have not been published previously and are not currently under review at another journal. All manuscripts must also be accompanied by an adequately compiled and signed Journal Publishing Agreement.

If the manuscript is accepted for publication in European Annals of Allergy and Clinical Immunology, the authors guarantee that it will not be published elsewhere in any other language without permission from the copyright holder.

The authors of manuscripts that include illustrations, tables and/or sections of text that have been published previously elsewhere must request permission to reproduce the material from the copyright holder. This permission must be presented in written form during submission of the manuscript. In the absence of such permission, all material received will be regarded as the authors' own work.

Manuscripts that report the results of research conducted on human subjects must include a declaration in the Materials and Methods section that the study protocol was approved by the competent Ethics Committee, that the study was conducted in accordance with the ethical standards established in the Declaration of Helsinki of 1946, and that informed consent was obtained from all participants before enrolment in the study. All details that could reveal the identity of a patient (including initials of the patient name and unnecessary reference to personal data such as occupation and residence) must be omitted from the text and illustrative materials. The patients must provide written informed consent to the publication (Consent Form).

If experiments have been conducted on animals, the study must have been conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals guidelines recommended by the World Health Organization (WHO) for the use of laboratory animals, and such adherence must be explicitly stated in the manuscript.



Edra S.p.A.  
Via G. Spadolini 7  
20141 Milano - Italia  
Telefono: +39 02 881841  
Telefax: +39 02 88184301  
edra\_spa@pec.it  
www.edraspa.it

Iscrizione al Registro delle  
Imprese di Milano n.2000629  
Partita Iva e C.F. 08056040960  
Cap. Soc. Euro 329.670,00 i.v.

The decision to publish a manuscript is based on a peer-review process, and acceptance of an article will be based on criteria of originality, relevance, and scientific content of the contribution. The authors may be requested to modify the text based on the comments of reviewers. Statements made in the manuscripts are the responsibility of the author and not of the editor. The opinions expressed in the articles are those of the authors and may not reflect the position of the editors.

Each author must complete and sign a **Conflicts of interest disclosure form**, which specifies all economic, personal and professional relationships that could become a conflict of interests, that could be perceived as a possible conflict of interests, or that could influence the work of the author described in the manuscript. The form must be sent with the manuscript and, if the article is accepted for publication, all of the declarations will appear after the Acknowledgements section of the article. The editorial office reserves the right to reject any manuscript that does not conform to the above-described instructions. The authors will be held responsible for any false declarations or noncompliance with the instructions specified above.

### **SUBMISSION PROCEDURE**

**We request that all manuscripts should be submitted online at: <http://eaaci.edmgr.com>**

Authors are also requested to return both completed and signed Journal Publishing Agreement and Conflict of interest disclosure forms by e-mail to Journal Publishing Editor [e.grignani@lswr.it](mailto:e.grignani@lswr.it)

#### **Cover letter**

For the purpose of publication, the Authors must sign a cover letter in which the following information is reported in a declaration signed by the corresponding Author:

- the manuscript has neither been previously published, nor under consideration for publication elsewhere; the Authors have obtained written permission for the reproduction of images, figures or algorithms protected by copyright; if the article is published, the Author's rights concerning the article itself will be transferred to the Editor;
- existence or not of economic or other types of **conflicts of interest** regarding the article presented (attach also the completed and signed Conflicts of interest disclosure form mentioned above);
- the manuscript was read and approved by all Authors;
- for original articles, formal approval by the local Ethics Committee of the research proposed for publication is available.

#### **Title page preparation (Word Format)**

Title page **must** contain:

- manuscript title;
- names of the Authors: full names of the authors and complete surnames of each Author; each Author's affiliation must be IN ENGLISH;
- name and **address** of the Institution where the work was carried out;
- Information about Corresponding author:
- **complete address**;
- ORCID Identification;
- e-mail address to which the PDF of the drafts will be sent.

## Manuscript preparation (Word Format)

The first page of the manuscript must contain:

- 1) - Abstract (about 850 characters, spaces included);
- Key words: indicate at least 5 key words.

The style of writing should conform to English usage and syntax. Authors whose mother tongue is not English are urged to have their manuscripts checked for linguistic correctness before submission.

Slang, technical jargon, obscure abbreviations and abbreviated phrasing should be avoided.

- An Impact Statement: it is a single sentence (30 words) that summarizes the most important findings of the work: it needs to complement the title.

2) On the pages that follow, develop the manuscript with the word line numbers to facilitate the reviewers, and as follows:

- Introduction: give a brief description of the scope and objectives of the proposed research.
- Materials and methods provide a detailed description of the materials and methodologies used, clarify all ethical aspects (see the General Principles and Ethical Aspects section).
- Results: present the results of the research clearly and exhaustively.
- Discussion: analyse the results obtained and their clinical implications.
- Conclusions: present the significance of the results and the final observations of the Authors.
- References
- Conflict of Interest: in this section indicate the existence or absence of economic or other types of conflicts of interest regarding the article presented.

### References

Editorial Office suggests to use references no older than 6 years (Reviews excluded). The aim is an up-to-date bibliography.

References should be in the order:

- the order number corresponding with that of appearance in the text;
- the author's surname(s), followed by initial or first name;
- the title of the work, in the original language;
- for journals: usual title abbreviations according to international nomenclature and in the order: year, volume number, issue number (in parenthesis), first and last page numbers of the work.

For example:

Bodtger U, Linnegerg A. Remission of allergic rhinitis: An 8-year observational study. *J Allergy Clin Immunol* 2004; 114(6):1384-8.

- for books: name of the author/editor, title, publisher/institution, town where published, first and last page number of the work.

For example:

Paupe J, Scheinman P (Eds). *Allergologie Pédiatrique*. Flammarion, Paris, 1988: 324-42.

When cited in the text, references should be written as follows: (1, 2) not superscript.

Do not write the references using uppercase, small caps or italics. For abbreviation of titles, use the international standards from Index Medicus.

NOTE: For the Letters to the Editor the abstract is not admitted and a maximum of about 1000 words a two tables are granted.

## Tables

All tables must be submitted separately from the primary manuscript. Add them in files in Word format. Tables must be identified and referred in the manuscript with roman numerals and accompanied by a brief caption (e.g. **table IV**). **At least 1 table is required, mostly in original article.**

**Tables will not be accepted in PowerPoint, PDF or JPG formats, which require retyping of the text for uniformity of style with journal graphics.**

## Figures

The figures (i.e., photographs, graphs, and diagrams, including flow charts) themselves should be submitted separately from the manuscript file (one file for each figure). Each figure should be numbered with an arabic numeral (according to its citation in the text). For composite figures, each component should be labeled with lowercase letters (e.g., **figure 1 a**). **At least 2 figures are required, mostly in original article.**

## Infographics

To summarize the key concepts, infographics could be added in reviews.

Use HELVETICA font for graphics' elements.

Photographs, graphs, diagrams, and flow charts must be supplied in one of the following formats: **JPG** (high resolution: min 300 dpi), **TIFF** (high resolution: min 400 dpi).

Scanned images must be acquired with high resolution and saved in a high-resolution format.

I

Illustrative material included in the article should ideally be unprotected by copyright. For tables or figures that have already been published (by the authors or others), permission to reproduce must be obtained from the copyright holder (in generally, the journal in which the material was originally published) and attached to the submission. Failure to obtain this permission prior to submission can delay publication of an accepted manuscript.

Authors should make sure that photographs of patients contain no identifying features. The patient must be asked to provide written informed consent to the publication of the photograph.

**In addition, the Publisher reserves the right to not publish images not conforming to these requirements, which could affect the graphical quality of the journal.**

**NOTE:** Figures must be presented separately, not inserted in the manuscript text and must not contain trade names or bibliographic references.

**Legends:** Captions for figures are to be provided in the text file at the end of the manuscript. **DO NOT** incorporate captions to figures.

## Acronyms, abbreviations, units of measurements

European Annals of Allergy and Clinical Immunology recognizes the adoption of the International Systems of Units (SI-Units). Acronyms, abbreviations, and units of measurements without a legend and/or incomprehensible are not permitted. When necessary, a list of abbreviations may be inserted after the abstract.

- Use 2 key words in the first 65 characters of the title and in the first 2 lines of the abstract.
- Other key words should be spread throughout the abstract (up to 6 times) and the manuscript in a well-contextualized way.
- Key words are single words and short sentences.
- Tool to consult to search key words: [GoogleTrends](#).

### **Acceptance of submissions**

Submitted contributions are accepted for publication on the basis of scientific interest and relevance for European Annals of Allergy and Clinical Immunology, at the final discretion of the Editor in Chief, who will have blinded written evaluations from at least two anonymous reviewers.

### **Informed Consent**

In articles describing clinical cases or studies on people it must be made explicit in the manuscript that the study was carried out in accordance with the ethical standards established in the Declaration of Helsinki, and that informed consent was obtained from all participants before enrolment in the study (see also the related section under General Principles).

### **Conflict of interests**

The Authors must declare the existence or absence of economic or other types of conflicts of interests after the "CONCLUSIONS" section of the manuscript.

### **Acknowledgements**

"ACKNOWLEDGEMENTS" of Institutions or persons, if present, must be inserted after the "CONCLUSIONS" section.

### **Fundings**

The Authors must indicate after the "CONCLUSIONS" or "ACKNOWLEDGEMENTS" sections if the study received funding or did not receive funding.

### **Proofreading**

Proofreading is the responsibility of the Authors regarding content and of the Editors regarding the technical part. The proofs for correction will be sent to the corresponding Author indicated in the manuscript. These must be corrected and returned to the editorial office by the date indicated in the accompanying letter and within 3 working days of their receipt.

After this deadline, ex officio correction and/or postponing of publication will occur, depending on the editorial priority of the Editor in Chief.

**Responses received after the indicated date and requests for sending to another or more than one Author, different from the one indicated in the manuscript, will not be accepted.**

**NOTE:** Proofreading corrections must avoid modifying the graphics already defined or modifying the content so to require a new peer-review process.

### **HOW TO WRITE AN INDEXABLE PAPER (SEO PRINCIPLES)**

- Do not use too long sentences. Alternating short and medium length sentences could be useful.
- Use 2 key words in the first 65 characters of the title and in the first 2 lines of the abstract.
- Other key words should be spread throughout the abstract (up to 6 times) and the manuscript in a well-contextualized way.
- Key words are single words and short sentences.
- Tool to consult to search key words: [GoogleTrends](#).

### **Acceptance of submissions**

Submitted contributions are accepted for publication on the basis of scientific interest and relevance for European Annals of Allergy and Clinical Immunology, at the final discretion of the Editor in Chief, who will have blinded written evaluations from at least two anonymous reviewers.

### **Informed Consent**

The study has to be conducted in accordance with the ethical standards established in the Declaration of Helsinki, and an informed consent have to be obtained from all participants before enrolment in the study (see also the related section under General Principles).

### **Conflict of interests**

The Authors must declare the existence or absence of economic or other types of conflicts of interests after the "CONCLUSIONS" section of the manuscript.

### **Acknowledgements**

"ACKNOWLEDGEMENTS" of Institutions or persons, if present, must be inserted after the "CONCLUSIONS" section.

### **Fundings**

The Authors must indicate after the "CONCLUSIONS" or ACKNOWLEDGEMENTS" sections if the study received funding or did not receive funding.

### **Proofreading**

Proofreading is the responsibility of the Authors regarding content and of the Editors regarding the technical part. The proofs for correction will be sent to the corresponding Author indicated in the manuscript. These must be corrected and returned to the editorial office by the date indicated in the accompanying letter and within 3 working days of their receipt.

After this deadline, ex officio correction and/or postponing of publication will occur, depending on the editorial priority of the Editor in Chief.

**Responses received after the indicated date and requests for sending to another or more than one Author, different from the one indicated in the manuscript, will not be accepted.**

**NOTE:** Proofreading corrections must avoid modifying the graphics already defined or modifying the content so to require a new peer-review process.